Coded Growth Innovation Center

Coded Growth Innovation Center Financial Leverage

The Financial Leverage (Equity Multiplier) of Coded Growth Innovation Center (DMSI) as of Oct 27, 2026 is 1.29.

Financial Leverage

1.29

Last updated:

Financial Leverage (Equity Multiplier) of Coded Growth Innovation Center is 2006 1.29 . Financial Leverage (Equity Multiplier) of Coded Growth Innovation Center was 2005 - . It decreases by % lower compared to the previous year.

The Coded Growth Innovation Center Financial Leverage history

The Coded Growth Innovation Center Financial Leverage history
YEARFinancial LeverageYoY
1.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Coded Growth Innovation Center Stock analysis

What does Coded Growth Innovation Center do? Dermisonics, Inc. generates revenue through its medical technology services, specifically focusing on transdermal drug delivery systems. The company offers both passive and active transdermal systems, which deliver medications through the skin into the bloodstream without liver metabolism, enabling lower dosing. Passive systems rely on natural diffusion, while active systems use physical force to enhance drug penetration. Dermisonics targets healthcare providers and pharmaceutical companies seeking innovative drug delivery solutions that improve patient compliance and therapeutic efficacy. The company's principal activity centers on developing and providing transdermal systems for drug delivery, emphasizing the avoidance of liver metabolism for certain medications. This approach allows for systemic effects via capillary penetration, catering to the needs of pharmaceutical firms looking to optimize drug formulations. Dermisonics operates as a development-stage company, focusing on advancing its transdermal delivery technology to meet market demands for more efficient drug administration methods. Dermisonics, Inc. serves the healthcare sector with its transdermal systems, which are designed to deliver drugs through skin patches. These systems are particularly beneficial for medications requiring lower dosing due to their ability to bypass liver metabolism. The company's product line includes both passive and active transdermal delivery systems, targeting pharmaceutical companies and healthcare providers who prioritize patient-friendly and effective drug delivery mechanisms. Coded Growth Innovation Center is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Coded Growth Innovation Center stock

Financial Leverage (Equity Multiplier) of Coded Growth Innovation Center is 1.29 in 2006.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Coded Growth Innovation Center since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Coded Growth Innovation Center with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Coded Growth Innovation Center

All Key Metrics — Coded Growth Innovation Center